For example, colon cancers that have a normally functioning version of a surface protein called KRAS are likely to respond to certain anti-epidermal growth factor receptor (EGFR) antibody therapies; those in which the protein is absent or non-functional are not. Here, EGFR is linked to colonic neoplasm.